
22nd Century Group XXII
Quarterly report 2026-Q1
added 05-07-2026
22nd Century Group Cash Conversion Cycle 2011-2026 | XXII
Annual Cash Conversion Cycle 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 | 19 | 113 | 63.7 | 83.7 | 40.6 | 16 | 18.7 | 46.4 | 51.5 | 59.3 | 896 | 1.07 K | -179 | -329 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 K | -329 | 139 |
Quarterly Cash Conversion Cycle 22nd Century Group
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 73 | 73.2 | 31.6 | - | 3.24 | -15.8 | -0.32 | - | 284 | 236 | 189 | - | 51.7 | 44.5 | 24.5 | - | 35.1 | 33.6 | 39 | 27 | 39 | 44 | 27.6 | 10.9 | 16 | 17.8 | 17.9 | 11.1 | 19.7 | 17.8 | 26.2 | 14.7 | 41.8 | 49.4 | 20.4 | 1.12 | 1.21 | 1.32 | 1.39 | 1.59 | 45.8 | 2.03 | 3.79 | - | 352 | - | - | - | 6 K | - | - | - | - | - | - | - | 20.4 | 44.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6 K | -15.8 | 186 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-3.12 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
149 | $ 1.73 | 5.18 % | $ 203 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
-3.74 K | $ 31.65 | 2.59 % | $ 2.1 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | ||
|
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 53.52 | 3.74 % | $ 4.81 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Compugen Ltd.
CGEN
|
-82.7 | $ 2.68 | 1.13 % | $ 250 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-981 | $ 0.78 | 14.04 % | $ 35.6 M | ||
|
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.32 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
115 | $ 31.66 | 1.18 % | $ 852 M | ||
|
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Celyad Oncology SA
CYAD
|
-55.7 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.08 | 0.9 % | $ 5.49 B | ||
|
Hutchison China MediTech Limited
HCM
|
95.8 | $ 11.72 | -0.26 % | $ 10.1 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | ||
|
Heron Therapeutics
HRTX
|
751 | $ 0.9 | 2.13 % | $ 150 M | ||
|
Anika Therapeutics
ANIK
|
192 | $ 14.76 | -0.87 % | $ 212 M | ||
|
Advaxis
ADXS
|
-82.3 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M |